Skip to main content
Erschienen in: Annals of Surgical Oncology 4/2006

01.04.2006

Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial

verfasst von: Lee Gravatt Wilke, MD, Linda M. McCall, MS, Katherine E. Posther, MD, Pat W. Whitworth, MD, Douglas S. Reintgen, MD, A. Marilyn Leitch, MD, Sheryl G. A. Gabram, MD, Anthony Lucci, MD, Charles E. Cox, MD, Kelly K. Hunt, MD, James E. Herndon II, PhD, Armando E. Giuliano, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

Background

American College of Surgeons Oncology Group Z0010 is a prospective multicenter trial designed to evaluate the prognostic significance of micrometastases in the sentinel lymph nodes and bone marrow aspirates of women with early-stage breast cancer. Surgical complications associated with the sentinel lymph node biopsy surgical procedure are reported.

Methods

Eligible patients included women with clinical T1/2N0M0 breast cancer. Surgical outcomes were available at 30 days and 6 months after surgery for 5327 patients. Patients who had a failed sentinel node mapping (n = 71, 1.4%) or a completion lymph node dissection (n = 814, 15%) were excluded. Univariate and multivariate analyses were performed to identify predictors for the measured surgical complications.

Results

In patients who received isosulfan blue dye alone (n = 783) or a combination of blue dye and radiocolloid (n = 4192), anaphylaxis was reported in .1% of subjects (5 of 4975). Other complications included axillary wound infection in 1.0%, axillary seroma in 7.1%, and axillary hematoma in 1.4% of subjects. Only increasing age and an increasing number of sentinel lymph nodes removed were significantly associated with an increasing incidence of axillary seroma. At 6 months, 8.6% of patients reported axillary paresthesias, 3.8% had a decreased upper extremity range of motion, and 6.9% demonstrated proximal upper extremity lymphedema (change from baseline arm circumference of >2 cm). Significant predictors for surgical complications at 6 months were a decreasing age for axillary paresthesias and increasing body mass index and increasing age for upper extremity lymphedema.

Conclusions

This study provides a prospective assessment of the sentinel lymph node biopsy procedure, as performed by a wide range of surgeons, demonstrating a low complication rate.
Literatur
1.
Zurück zum Zitat Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220:391–401PubMed Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220:391–401PubMed
2.
Zurück zum Zitat Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med 1998; 339:941–6CrossRefPubMed Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med 1998; 339:941–6CrossRefPubMed
3.
Zurück zum Zitat Tafra L, Lannin D, Swanson M, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 2001; 233:51–9PubMed Tafra L, Lannin D, Swanson M, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 2001; 233:51–9PubMed
4.
Zurück zum Zitat Shivers S, Cox C, Leight G, et al. Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann Surg Oncol 2002; 9:248–55CrossRefPubMed Shivers S, Cox C, Leight G, et al. Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann Surg Oncol 2002; 9:248–55CrossRefPubMed
5.
Zurück zum Zitat Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999; 91:368–73PubMed Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999; 91:368–73PubMed
6.
Zurück zum Zitat Morrow M, Rademaker AW, Bethke KP, et al. Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery 1999; 126:714–22PubMed Morrow M, Rademaker AW, Bethke KP, et al. Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery 1999; 126:714–22PubMed
7.
Zurück zum Zitat Bergkvist L, Frisell J, Liljegren G, Celebioglu F, Damm S, Thorn M. Multicentre study of detection and false-negative rates in sentinel node biopsy for breast cancer. Br J Surg 2001; 88:1644–8CrossRefPubMed Bergkvist L, Frisell J, Liljegren G, Celebioglu F, Damm S, Thorn M. Multicentre study of detection and false-negative rates in sentinel node biopsy for breast cancer. Br J Surg 2001; 88:1644–8CrossRefPubMed
8.
Zurück zum Zitat McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000; 18:1644–8 McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000; 18:1644–8
9.
Zurück zum Zitat Cody HS, Fey J, Akhurst T, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol 2001; 8:13–9PubMed Cody HS, Fey J, Akhurst T, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol 2001; 8:13–9PubMed
10.
Zurück zum Zitat Kelley MC, Hansen N, McMasters KM. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Am J Surg 2004; 188:49–61CrossRefPubMed Kelley MC, Hansen N, McMasters KM. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Am J Surg 2004; 188:49–61CrossRefPubMed
11.
Zurück zum Zitat Giuliano AE, Haigh PI, Breannan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000; 18:2553–9PubMed Giuliano AE, Haigh PI, Breannan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000; 18:2553–9PubMed
12.
Zurück zum Zitat Meric F, Buchholz TA, Mirza NQ, et al. Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol 2002; 9:543–9CrossRefPubMed Meric F, Buchholz TA, Mirza NQ, et al. Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol 2002; 9:543–9CrossRefPubMed
13.
Zurück zum Zitat Gervasoni JE, Charu T, Chung MA, Cady B. Axillary dissection in the context of the biology of lymph node metastases. Am J Surg 2000; 180:278–83CrossRefPubMed Gervasoni JE, Charu T, Chung MA, Cady B. Axillary dissection in the context of the biology of lymph node metastases. Am J Surg 2000; 180:278–83CrossRefPubMed
14.
Zurück zum Zitat Rietman JS, Dijkstra PU, Geertzen JH, et al. Short-term morbidity of the upper limb after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast carcinoma. Cancer 2003; 98:690–6CrossRefPubMed Rietman JS, Dijkstra PU, Geertzen JH, et al. Short-term morbidity of the upper limb after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast carcinoma. Cancer 2003; 98:690–6CrossRefPubMed
15.
Zurück zum Zitat Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349:546–53CrossRefPubMed Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349:546–53CrossRefPubMed
16.
Zurück zum Zitat Smith RA, Duffy SW, Gabe R, et al. The randomized trials of breast cancer screening: what have we learned? Radiol Clin North Am 2004; 42:793–806CrossRefPubMed Smith RA, Duffy SW, Gabe R, et al. The randomized trials of breast cancer screening: what have we learned? Radiol Clin North Am 2004; 42:793–806CrossRefPubMed
17.
18.
Zurück zum Zitat Rampaul RS, Mullinger K, Macmillan RD, et al. Incidence of clinically significant lymphoedema as a complication following surgery for primary operable breast cancer. Eur J Cancer 2003; 39:2165–7CrossRefPubMed Rampaul RS, Mullinger K, Macmillan RD, et al. Incidence of clinically significant lymphoedema as a complication following surgery for primary operable breast cancer. Eur J Cancer 2003; 39:2165–7CrossRefPubMed
19.
Zurück zum Zitat Thomson AM, Air M, Jack WJL, et al. Arm morbidity after breast conservation and axillary therapy. Breast 1995; 4:273–6 Thomson AM, Air M, Jack WJL, et al. Arm morbidity after breast conservation and axillary therapy. Breast 1995; 4:273–6
20.
Zurück zum Zitat Liljegren G, Holmberg L. Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage I. Results from a randomised trial. Eur J Cancer 1997; 33:193–9CrossRefPubMed Liljegren G, Holmberg L. Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage I. Results from a randomised trial. Eur J Cancer 1997; 33:193–9CrossRefPubMed
21.
Zurück zum Zitat Warmuth MA, Bowen G, Prosnitz LR, et al. Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer 1998; 83:1362–8CrossRefPubMed Warmuth MA, Bowen G, Prosnitz LR, et al. Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer 1998; 83:1362–8CrossRefPubMed
22.
Zurück zum Zitat Kuehn T, Klauss W, Darsow M, et al. Long-term morbidity following axillary dissection in breast cancer patients—clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat 2000; 64:275–86CrossRefPubMed Kuehn T, Klauss W, Darsow M, et al. Long-term morbidity following axillary dissection in breast cancer patients—clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat 2000; 64:275–86CrossRefPubMed
23.
Zurück zum Zitat Mansel RE, Goyal A, Fallowfield L, et al. Sentinel node biopsy versus standard axillary treatment: results of the randomized multicenter UK ALMANAC trial. Breast Cancer Res Treat 2004; 88:S13 Mansel RE, Goyal A, Fallowfield L, et al. Sentinel node biopsy versus standard axillary treatment: results of the randomized multicenter UK ALMANAC trial. Breast Cancer Res Treat 2004; 88:S13
24.
Zurück zum Zitat Julian TB, Krag D, Brown A, et al. Preliminary technical results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. Breast Cancer Res Treat 2004; 88:S11 Julian TB, Krag D, Brown A, et al. Preliminary technical results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. Breast Cancer Res Treat 2004; 88:S11
25.
Zurück zum Zitat Newman LA. Lymphatic mapping and sentinel lymph node biopsy in breast cancer patients: a comprehensive review of variations in performance and technique. J Am Coll Surg 2004; 199:804–16PubMed Newman LA. Lymphatic mapping and sentinel lymph node biopsy in breast cancer patients: a comprehensive review of variations in performance and technique. J Am Coll Surg 2004; 199:804–16PubMed
26.
Zurück zum Zitat Montgomery LL, Thorne AC, Van Zee KJ, et al. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg 2002; 95:385–8PubMed Montgomery LL, Thorne AC, Van Zee KJ, et al. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg 2002; 95:385–8PubMed
27.
Zurück zum Zitat Cimmino VM, Brown AC, Szocik JF, et al. Allergic reactions to isosulfan blue during sentinel node biopsy—a common event. Surgery 2001; 130:439–42CrossRefPubMed Cimmino VM, Brown AC, Szocik JF, et al. Allergic reactions to isosulfan blue during sentinel node biopsy—a common event. Surgery 2001; 130:439–42CrossRefPubMed
28.
Zurück zum Zitat Albo D, Wayne JD, Hunt KK, et al. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg 2001; 182:393–8CrossRefPubMed Albo D, Wayne JD, Hunt KK, et al. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg 2001; 182:393–8CrossRefPubMed
29.
Zurück zum Zitat Efron P, Knudsen E, Hirshorn S, Copeland EM. Anaphylactic reaction to isosulfan blue used for sentinel node biopsy: case report and literature review. Breast J 2002; 8:396–9CrossRefPubMed Efron P, Knudsen E, Hirshorn S, Copeland EM. Anaphylactic reaction to isosulfan blue used for sentinel node biopsy: case report and literature review. Breast J 2002; 8:396–9CrossRefPubMed
30.
Zurück zum Zitat Bold RJ, Mansfield PF, Berger DH, et al. Prospective, randomized, double-blind study of prophylactic antibiotics in axillary lymph node dissection. Am J Surg 1998; 176:239–43CrossRefPubMed Bold RJ, Mansfield PF, Berger DH, et al. Prospective, randomized, double-blind study of prophylactic antibiotics in axillary lymph node dissection. Am J Surg 1998; 176:239–43CrossRefPubMed
31.
Zurück zum Zitat Rotstein C, Ferguson R, Cummings KM, et al. Determinants of clean surgical wound infections for breast procedures at an oncology center. Infect Control Hosp Epidemiol 1992; 13:207–14PubMed Rotstein C, Ferguson R, Cummings KM, et al. Determinants of clean surgical wound infections for breast procedures at an oncology center. Infect Control Hosp Epidemiol 1992; 13:207–14PubMed
32.
Zurück zum Zitat Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993; 11:1536–44PubMed Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993; 11:1536–44PubMed
33.
Zurück zum Zitat Petrek JA, Peters MM, Nori S, et al. Axillary lymphadenectomy: a prospective randomized trial of thirteen factors influencing drainage, including early or delayed arm mobilization. Arch Surg 1990; 125:378–82PubMed Petrek JA, Peters MM, Nori S, et al. Axillary lymphadenectomy: a prospective randomized trial of thirteen factors influencing drainage, including early or delayed arm mobilization. Arch Surg 1990; 125:378–82PubMed
34.
Zurück zum Zitat Gonzalez EA, Saltzstein EC, Riedner CS, et al. Seroma formation following breast cancer surgery. Breast J 2003; 9:385–8CrossRefPubMed Gonzalez EA, Saltzstein EC, Riedner CS, et al. Seroma formation following breast cancer surgery. Breast J 2003; 9:385–8CrossRefPubMed
35.
Zurück zum Zitat Zavotsky, Jones RC, Brennan MB, Giuliano AE. Evaluation of axillary lymphadenectomy without axillary drainage for patients undergoing breast-conserving therapy. Ann Surg Oncol 1998; 5:227–31. CrossRefPubMed Zavotsky, Jones RC, Brennan MB, Giuliano AE. Evaluation of axillary lymphadenectomy without axillary drainage for patients undergoing breast-conserving therapy. Ann Surg Oncol 1998; 5:227–31. CrossRefPubMed
36.
Zurück zum Zitat Burak WE Jr, Goodman PS, Young DC, et al. Seroma formation following axillary dissection for breast cancer: risk factors and lack of influence of bovine thrombin. J Surg Oncol 1997; 64:27–31CrossRefPubMed Burak WE Jr, Goodman PS, Young DC, et al. Seroma formation following axillary dissection for breast cancer: risk factors and lack of influence of bovine thrombin. J Surg Oncol 1997; 64:27–31CrossRefPubMed
37.
Zurück zum Zitat Jeffrey SS, Goodson WH, Ikeda DM, et al. Axillary lymphadenectomy for breast cancer without axillary drainage. Arch Surg 1995; 130:909–13PubMed Jeffrey SS, Goodson WH, Ikeda DM, et al. Axillary lymphadenectomy for breast cancer without axillary drainage. Arch Surg 1995; 130:909–13PubMed
38.
Zurück zum Zitat Roses DF, Brooks AD, Harris MN, et al. Complications of level I and II axillary dissection in the treatment of carcinoma of the breast. Ann Surg 1999; 230:194–201CrossRefPubMed Roses DF, Brooks AD, Harris MN, et al. Complications of level I and II axillary dissection in the treatment of carcinoma of the breast. Ann Surg 1999; 230:194–201CrossRefPubMed
39.
Zurück zum Zitat Burak WE, Hollenbeck ST, Zervos EE, et al. Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg 2002; 183:23–7CrossRefPubMed Burak WE, Hollenbeck ST, Zervos EE, et al. Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg 2002; 183:23–7CrossRefPubMed
40.
Zurück zum Zitat Schrenk P, Rieger R, Shamiyeh A, et al. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000; 88:608–14CrossRefPubMed Schrenk P, Rieger R, Shamiyeh A, et al. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000; 88:608–14CrossRefPubMed
41.
Zurück zum Zitat Kakuda JT, Stuntz M, Trivedi V, et al. Objective assessment of axillary morbidity in breast cancer treatment. Am Surg 1999; 65:995–8PubMed Kakuda JT, Stuntz M, Trivedi V, et al. Objective assessment of axillary morbidity in breast cancer treatment. Am Surg 1999; 65:995–8PubMed
42.
Zurück zum Zitat Stotter A, Chandler T. Breast cancer: outcome audit of axillary management in 1991. Eur J Surg Oncol 1999; 25:261–4PubMed Stotter A, Chandler T. Breast cancer: outcome audit of axillary management in 1991. Eur J Surg Oncol 1999; 25:261–4PubMed
43.
Zurück zum Zitat Keramopoulos A, Tsionou C, Minaretzis D, et al. Arm morbidity following treatment of breast cancer with total axillary dissection: a multivariated approach. Oncology 1993; 50:445–9PubMed Keramopoulos A, Tsionou C, Minaretzis D, et al. Arm morbidity following treatment of breast cancer with total axillary dissection: a multivariated approach. Oncology 1993; 50:445–9PubMed
44.
Zurück zum Zitat Swenson KK, Nissen MJ, Ceronsky C, et al. Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer. Ann Surg Oncol 2002; 9:745–53CrossRefPubMed Swenson KK, Nissen MJ, Ceronsky C, et al. Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer. Ann Surg Oncol 2002; 9:745–53CrossRefPubMed
45.
Zurück zum Zitat Krynyckyi BR, Shim J, Lim I. Short-term morbidity of the upper limb after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast carcinoma (letter). Cancer 2004; 101:2367–8CrossRefPubMed Krynyckyi BR, Shim J, Lim I. Short-term morbidity of the upper limb after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast carcinoma (letter). Cancer 2004; 101:2367–8CrossRefPubMed
46.
Zurück zum Zitat Mansel RE, Goyal A, Newcombe RG, et al. Objective assessment of lymphedema, shoulder function and sensory deficit after sentinel node biopsy for invasive breast cancer: ALMANAC trial. Breast Cancer Res Treat 2004; 88:S12. Mansel RE, Goyal A, Newcombe RG, et al. Objective assessment of lymphedema, shoulder function and sensory deficit after sentinel node biopsy for invasive breast cancer: ALMANAC trial. Breast Cancer Res Treat 2004; 88:S12.
47.
Zurück zum Zitat Kissin MW, della Rovere QG, Easton D, Westbury G. Risk of lymphedema following the treatment of breast cancer. Br J Surg 1986; 73:580–4PubMed Kissin MW, della Rovere QG, Easton D, Westbury G. Risk of lymphedema following the treatment of breast cancer. Br J Surg 1986; 73:580–4PubMed
48.
Zurück zum Zitat Delouche G, Bachelot F, Premont M, Kurtz JM. Conservation treatment of early breast cancer: long term results and complications. Int J Radiat Oncol Biol Phys 1987; 13:29–34PubMed Delouche G, Bachelot F, Premont M, Kurtz JM. Conservation treatment of early breast cancer: long term results and complications. Int J Radiat Oncol Biol Phys 1987; 13:29–34PubMed
49.
Zurück zum Zitat Larson D, Weinstein M, Goldberg I, et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 1986; 12:1575–82PubMed Larson D, Weinstein M, Goldberg I, et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 1986; 12:1575–82PubMed
50.
Zurück zum Zitat Petrek JA, Senie RT, Peters M, et al. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 2001; 92:1368–77CrossRefPubMed Petrek JA, Senie RT, Peters M, et al. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 2001; 92:1368–77CrossRefPubMed
51.
Zurück zum Zitat Passik SD, McDonald MV. Psychosocial aspects of upper extremity lymphedema in women treated for breast carcinoma. Cancer 1998; 83:2817–20CrossRefPubMed Passik SD, McDonald MV. Psychosocial aspects of upper extremity lymphedema in women treated for breast carcinoma. Cancer 1998; 83:2817–20CrossRefPubMed
52.
Zurück zum Zitat Tobin MB, Lacey HJ, Meyer L, Mortimer PS. The psychosocial morbidity of breast cancer-related arm swelling. Psychological morbidity of lymphoedema. Cancer 1993; 72:3248–52PubMed Tobin MB, Lacey HJ, Meyer L, Mortimer PS. The psychosocial morbidity of breast cancer-related arm swelling. Psychological morbidity of lymphoedema. Cancer 1993; 72:3248–52PubMed
53.
Zurück zum Zitat Velanovich V, Szymanski W. Quality of life of breast cancer patients with lymphedema. Am J Surg 1999; 177:184–7CrossRefPubMed Velanovich V, Szymanski W. Quality of life of breast cancer patients with lymphedema. Am J Surg 1999; 177:184–7CrossRefPubMed
54.
Zurück zum Zitat Kwan W, Jackson J, Weir LM, et al. Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol 2002; 20:4242–8CrossRefPubMed Kwan W, Jackson J, Weir LM, et al. Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol 2002; 20:4242–8CrossRefPubMed
55.
Zurück zum Zitat Silberman AW, McVay C, Cohen JS, et al. Comparative morbidity of axillary lymph node dissection and the sentinel lymph node technique: implications for patients with breast cancer. Ann Surg 2004; 240:1–6PubMed Silberman AW, McVay C, Cohen JS, et al. Comparative morbidity of axillary lymph node dissection and the sentinel lymph node technique: implications for patients with breast cancer. Ann Surg 2004; 240:1–6PubMed
56.
Zurück zum Zitat Sener SF, Winchester DJ, Martz CH, et al. Lymphedema after sentinel lymphadenectomy for breast carcinoma. Cancer 2001; 92:748–52CrossRefPubMed Sener SF, Winchester DJ, Martz CH, et al. Lymphedema after sentinel lymphadenectomy for breast carcinoma. Cancer 2001; 92:748–52CrossRefPubMed
57.
Zurück zum Zitat Haid A, Köberle-Wührer R, Knauer M, et al. Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation. Breast Cancer Res Treat 2002; 73:31–6CrossRefPubMed Haid A, Köberle-Wührer R, Knauer M, et al. Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation. Breast Cancer Res Treat 2002; 73:31–6CrossRefPubMed
58.
Zurück zum Zitat Werner RS, McCormick B, Petrek JA, et al. Arm edema in conservatively managed breast cancer: obesity is a major predictive factor. Radiology 1991; 180:177–84PubMed Werner RS, McCormick B, Petrek JA, et al. Arm edema in conservatively managed breast cancer: obesity is a major predictive factor. Radiology 1991; 180:177–84PubMed
Metadaten
Titel
Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial
verfasst von
Lee Gravatt Wilke, MD
Linda M. McCall, MS
Katherine E. Posther, MD
Pat W. Whitworth, MD
Douglas S. Reintgen, MD
A. Marilyn Leitch, MD
Sheryl G. A. Gabram, MD
Anthony Lucci, MD
Charles E. Cox, MD
Kelly K. Hunt, MD
James E. Herndon II, PhD
Armando E. Giuliano, MD
Publikationsdatum
01.04.2006
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2006
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2006.05.013

Weitere Artikel der Ausgabe 4/2006

Annals of Surgical Oncology 4/2006 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.